Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $755.50
Acquisition to Strengthen Transplant and Oncology Businesses CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme...
CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX:...
AnorMED Board Recommends Shareholders Accept Genzyme Offer LANGLEY, BC, Nov. 3 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the...
SEATTLE, Oct. 26 /PRNewswire/ -- Koronis Pharmaceuticals, Inc. today announced the appointment of Stephen Becker, M.D., as chief medical...
VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that it has completed enrollment in the second...
Genzyme to Gain Late-Stage Transplantation Product Candidate VANCOUVER, BC, and CAMBRIDGE, MA, Oct. 17 /PRNewswire-FirstCall/ -- Genzyme...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the...
VANCOUVER, Oct. 10 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) announced today that it has received a proposal from Genzyme...
CAMBRIDGE, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that it has informed the Board of...
CAMBRIDGE, Mass., Oct. 6 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) announced today that it has extended its offer to acquire...
VANCOUVER, Oct. 5 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) announced today that its Board of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.